YBX1 and neoplasm: After 8–10 weeks, in vivo imaging revealed significantly lower tumor bioluminescence in YBX1-knockdown mice (Fig. 3E, F), and the weight of the tumors in situ was also smaller than that of the control group (Fig. 3G), suggesting suppressed tumor growth.